Advanced Filters
noise

Saint-Leonard, Canada Clinical Trials

A listing of Saint-Leonard, Canada clinical trials actively recruiting patients volunteers.

Found 630 clinical trials
C Catherine Birken, MD, M.Sc., FRCPC

TARGet Kids!: Measuring Nutrition in Young Preschool Children in the Primary Care Practice Setting

TARGet Kids! (The Applied Research Group for Kids) is a research study enrolling healthy children aged 0-5 years. The aim of the TARGet Kids! registry is to link early life exposures to health problems including obesity, micronutrient deficiencies, and developmental problems. TARGet Kids! represents an innovative collaboration between child health …

- 5 years of age All Phase N/A

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

years of age All Phase N/A
C Constantin Polychronakos, MD

Monogenic Diabetes Misdiagnosed as Type 1

The study has two aims: To (1a) determine the frequency of monogenic diabetes misdiagnosed as type 1 diabetes (T1D) and (2) to define an algorithm for case selection. To discover novel genes whose mutations cause monogenic diabetes misdiagnosed as T1D.

1 - 25 years of age All Phase N/A
J Joseph Flynn

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to …

- 20 years of age All Phase N/A
M Manuel Flores, PhD

Montreal Immune-Related Adverse Events (MIRAE) Study

Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related adverse events (irAEs). irAEs can lead to treatment discontinuation, or can be life-threatening …

18 - 100 years of age All Phase N/A
S Stephanie Fevrier, MSc

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring >48 hours of age). In Canada, ~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every …

21 - 32 years of age All Phase N/A
C Carole Fortier, RN

Canadian Fabry Disease Initiative (CFDI) National Registry

CFDI NATIONAL REGISTRY Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A, persons with Fabry Disease develop severe neuropathic …

5 - 85 years of age All Phase N/A
D Diane Trudel

Evaluation of Technological Innovation in Radiotherapy

Prospective cohort study of patients receiving standard-care radiotherapy is paramount to a better understanding of radiation effects and longterm outcomes. The primary objective is to determine the feasibility of establishing infrastructure to systematically collect clinical data, patient-reported outcomes, and imaging data from daily radiotherapy practice. Secondary objectives are to provide …

18 years of age All Phase N/A

The European Paediatric Network for Haemophilia Management ( PedNet Registry)

Rationale Haemophilia is a rare disease; to improve knowledge international collaboration is needed. Well-defined clinical data will be collected from complete cohorts in order to prevent selection bias. Objective To collect data on bleeding during neonatal period, endogenous (genetic) and exogenous (treatment-related) determinants of inhibitor development and long term outcome.

years of age All Phase N/A
M Matthias G Friedrich, MD

A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease

This study aims to identify and assess new CMR techniques that can improve current CMR protocols.

18 years of age All Phase N/A

Simplify language using AI